An Adaptive Phase I/II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV
Latest Information Update: 03 Jan 2024
At a glance
- Drugs AZD 1222 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms COV005
- 06 Nov 2023 According to Barinthus Biotherapeutics media release, Vaccitech has changed its name to Barinthus Biotherapeutics .
- 01 Jan 2023 Results (n=174) assessing the SARS-CoV-2 specific T-cell responses 14 days after single-dose ChAdOx1 nCoV-19 (AZD1222) vaccination in black Africans with and without HIV in South Africa, as well as determine the effect of AZD1222 vaccination on cell-mediated immune responses in people with HIV (PWH) with prior SARS-CoV-2 infection, published in the AIDS.
- 16 Mar 2021 Results published in the New England Journal of Medicine